# Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.

> **NCT06417801** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 70 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06417801
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06417801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06417801, "Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06417801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*